A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19

Inclusion Criteria: * Male or female patients, age 18 years or older on the day of signing the informed consent form. * Agrees to admission to an in-patient facility for monitoring from Days 1 to 8, inclusive. * Symptoms of mild illness with COVID-19 without shortness of breath, dyspnea, or clinical signs indicative of more serious COVID-19. * Laboratory confirmed SARS-CoV-2 infection within 4 days prior to the screening visit or during the 7-day screening period. * Respiratory rate \< 20 breaths per minute, heart rate \< 90 beats per minute (bpm). * Oxygen saturation by pulse oximetry \> 93% on room air. * Body mass index \< 35 kg/m2. * Estimated glomerular filtration rate (eGFR) ≥ 30 mL/min. * Alanine transaminase (ALT) or aspartate transaminase (AST) \< 2 x upper limit of normal (ULN) and total bilirubin \< 1.5 x ULN. * Agrees to not participate in another clinical trial for the treatment of COVID-19 while on study unless the patient's condition has worsened and is considered to be moderate, severe, or critical by the Investigator. Exclusion Criteria: * Shortness of breath, hypoxia, or signs of serious lower airway disease. * C-reactive protein, lactate dehydrogenase (LDH), or interleukin-6 (IL-6) \> 1.5 x ULN. * D-dimer or ferritin \> 1.5 x ULN. * Imminently requiring, or currently on, mechanical ventilation or extracorporeal membrane oxygenation (ECMO). * Systolic blood pressure \< 90 mm Hg or diastolic blood pressure \< 60 mm Hg. * Evidence of acute respiratory distress syndrome (ARDS) or systemic inflammatory response syndrome (SIRS)/shock. * Known cardiovascular history, including unstable or deteriorating cardiac disease. * Autoimmune disease. * History of pulmonary embolism (PE), deep vein thrombosis (DVT), or prior clinically significant venous or non-cerebrovascular accident/transient ischemic attack arterial thromboembolic event. * Central nervous system disease or dysfunction. * Requirement for \> 2 anti-hypertensive medications. * Unwilling to refrain from alcohol consumption from Day 1 of admission to the in-patient facility until discharge from the facility. * Adrenal insufficiency. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.